Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks -       If approved, lanadelumab would be the first monoclonal antibody for the preventive treatment of...

Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema FOR US MEDIA ONLY  -  In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an 87% reduction in mean monthly attacks vs. placebo (0.26 vs. 1.97, n=27 vs. n=41) -  All secondary...